Sorrento Therapeutics Inc (SRNE)

[dia76ca]

The following post by Paul is worth reading. My only response is that the alleged "valuation" is like valuing McDonald's and omitting earnings from hamburgers and fries!
"Here is a DAWSON JAMES research update from Dec 10, 2020. The conclusion at the time was a very conservative $21 price target, and they applied a 30% discount rate. They also assumed a success rate of just 50% for COVI-SHIELD and RTX.

-SP102 (fast tracked) approval first quarter next year was not included

-Abivertinib (NSCLS) approval first quarter next year was not included

-Abivertinib (NSCLS) China approval second or third quarter this year was not included

-Abivertinib other indications in various stages of study were not included or ACEA BO and whatever else it brought to the table

-AMG not included (FDA filing was accepted at the time, but it had yet to begin trials. Now in P2. DARPA.

-COVIDROP not FDA accepted until 2021. Now in P2 in UK & US.

-STIX Mexico EUA, and probability for other Latin America markets; Europe (CE); US?

-MSC (not included) Brazil Pivotal P2 and likely EUA this year. EUA US?

-Abivertinib (covid) P2 data rollout at anytime, and potential EUA. Not included.

-I am leaving out licensing agreements, potential ANP BO, shares in other companies, potential arbitration ruling, partnerships, various other trials, antibody library, etc…

So folks, when I hear it will take 2-3 years before a revenue stream or I’m selling when the SP hits $20-30 dollars this year, I just laugh at the manipulation. At the investor unwilling to do their dd or should I say trader instead of investor. Looking for the quick buck when there’s a bag of gold near by. While the cream of the cream institutional investors are lifting their shares, all that some retail investors can see is a few quick easy dollars. The SP will rise well over $21 this year, and continue into next year. Triple digits. Yes. Maybe some folks should do their dd.

https://dawsonjames.com/wp-content/uploads/2020/12/SRNE.DJ_.12.10.2020.1.pdf?fbclid=IwAR1mxz-f-hDvM0N3G_cbvynm_a7HaVvAti39FHGdEu2QR6tlv8_yVk86Wog